In adults with metabolic dysfunction‑associated steatohepatitis (MASLD) who have biopsy‑proven NASH with fibrosis stage 2‑3 (or stage 1 with significant inflammation) and meet BMI criteria (≥ 30 kg/m² or ≥ 27 kg/m² with type 2 diabetes), what are the indications for initiating semaglutide therapy?

Semaglutide for MASLD: Current Indications

Semaglutide should be prescribed for adults with MASLD when they meet FDA-approved indications for type 2 diabetes (BMI ≥ 27 kg/m² with T2DM) or obesity (BMI ≥ 30 kg/m²), NOT as a MASH-targeted therapy, even in patients with biopsy-proven NASH and fibrosis stage 2-3. 1

The Critical Distinction: Cardiometabolic vs. Liver-Targeted Therapy

The 2024 EASL-EASD-EASO guidelines are unequivocal on this point: GLP-1 receptor agonists (including semaglutide) cannot currently be recommended as MASH-targeted therapies due to the absence of formal demonstration of histological improvement in large, well-conducted phase III trials at the time these guidelines were published 1. However, the guidelines strongly recommend that GLP-1RAs should be used for their respective indications—namely type 2 diabetes and obesity—as their use improves cardiometabolic outcomes 1.

Why This Matters Clinically

This distinction is not semantic—it fundamentally changes how you approach prescribing:

• If your patient has T2DM with BMI ≥ 27 kg/m² OR obesity with BMI ≥ 30 kg/m²: Prescribe semaglutide for these indications. The liver benefits are a welcome secondary effect 2.

• If your patient has biopsy-proven NASH F2-F3 but does NOT meet BMI/diabetes criteria: The guidelines do not support semaglutide as a liver-specific therapy, despite emerging trial data 1.

The Evidence Landscape

Recent Trial Data vs. Guideline Recommendations

The phase 3 trial data shows impressive histological benefits: semaglutide 2.4 mg achieved 62.9% MASH resolution without fibrosis worsening (vs. 34.3% placebo) and 36.8% fibrosis improvement (vs. 22.4% placebo) in patients with F2-F3 MASH 3. However, these results came after the 2024 guideline publication, explaining the apparent disconnect.

The guidelines explicitly note that "in case of substantial weight loss induced by GLP1RAs, a hepatic histological benefit could be expected, although this has not been extensively documented so far" 1. This acknowledges the mechanism but maintains the position that GLP-1RAs are not yet validated as MASH-targeted therapies.

Practical Algorithm for Prescribing Semaglutide in MASLD Patients

Step 1: Assess Cardiometabolic Indications FIRST

• BMI ≥ 30 kg/m² → Semaglutide indicated for obesity
• BMI ≥ 27 kg/m² + T2DM → Semaglutide indicated for diabetes/obesity
• T2DM alone (any BMI) → Semaglutide indicated for glycemic control

Step 2: Document Liver Disease Severity

• Use FIB-4 score and transient elastography to stage fibrosis
• Liver biopsy if available confirms NASH and fibrosis stage
• This informs prognosis but does NOT independently justify semaglutide prescription under current guidelines

Step 3: Consider Resmetirom for Liver-Targeted Therapy

If the patient has non-cirrhotic MASH with significant fibrosis (stage ≥2) and does NOT meet semaglutide's cardiometabolic indications, resmetirom is the guideline-recommended MASH-targeted therapy 1, 4. This is the only FDA-approved drug specifically for MASH with moderate to advanced fibrosis.

Step 4: Optimize Lifestyle and Comorbidities

Regardless of pharmacotherapy:

• Target ≥5% weight loss (≥7-10% for fibrosis improvement)
• ≥150 minutes/week moderate-intensity physical activity
• Mediterranean or low-carbohydrate diet
• Manage hypertension, dyslipidemia, and diabetes aggressively 1, 2

Common Pitfalls to Avoid

1. Don't prescribe semaglutide "for NASH" if the patient doesn't meet BMI/diabetes criteria—this is off-label use not supported by current guidelines, despite promising trial data.

2. Don't assume all MASLD patients need semaglutide—80.9% of MASLD patients and 95.4% of fibrotic MASH patients already meet conventional obesity/diabetes indications 5. The new MASH indication adds minimal additional eligibility.

3. Don't use semaglutide in cirrhotic MASH—no MASH-targeted pharmacotherapy is currently recommended for cirrhotic stage disease 1.

4. Don't ignore cardiovascular risk—MASLD patients die primarily from cardiovascular disease, not liver disease. Semaglutide's cardiovascular benefits (demonstrated in SUSTAIN-6 and SELECT trials) may be more important than liver histology 6.

The Real-World Reality

In practice, the overlap between metabolic comorbidities and MASLD is extensive. Research shows that 80.3% of patients with biopsy-proven F2-F3 fibrosis already qualify for semaglutide based on obesity or diabetes alone 5. This means most patients with fibrotic MASH who would benefit from semaglutide already have a clear indication for it.

For the minority who have isolated fibrotic MASH without obesity or diabetes, the current guideline-based approach prioritizes resmetirom as the liver-targeted agent, with semaglutide reserved for its approved cardiometabolic indications 1, 4.

The field is evolving rapidly—FDA approval of semaglutide specifically for MASH may change these recommendations, but until then, prescribe semaglutide for what it's approved for: diabetes and obesity in patients who happen to have MASLD, not as a primary liver therapy.